BioWorld

Dec. 27, 2005

View Archived Issues

Experimental Study Supports Population Selection In Viruses

Read More

Alexza Files For $86.25M IPO To Carry Aerosol Drug Work

Read More

Holiday notice

Read More

Appointments And Advancements

Read More

Other News To Note

Read More

Progenics, Wyeth Sign MNTX Agreement Worth Up To $416M

Progenics Pharmaceuticals Inc. picked up a worldwide partner for methylnaltrexone (MNTX), its investigational treatment of opioid-induced side effects, signing a deal with Wyeth Pharmaceuticals for up to $416 million. (BioWorld Today) Read More

EntreMed Acquiring Cancer Company Miikana For $21M

Read More